Physician profile
Stephen E Robbins
NPI 1790791713
$188,608.51
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136K · 2020: $1,539 · 2021: $35K · 2022: $15.19 · 2023: $134 · 2024: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,750.00 |
| Food and Beverage | $134.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $122,360.75 | 2019 | |
| Medtronic, INC. | $25,928.71 | 2021 | |
| Surgalign Spine Technologies, INC. | $17,000.00 | 2019-2021 | |
| Innovasis INC | $15,841.13 | 2023-2024 | |
| Premia Spine, LTD. | $5,349.39 | 2021 | |
| Rti Surgical, INC | $2,000.00 | 2021 | |
| Zimmer Biomet Holdings, INC. | $44.31 | 2019-2020 | |
| Heraeus Medical, LLC. | $31.68 | 2022-2023 | Palacos |
| Cerapedics INC. | $26.55 | 2023 | I-Factor Peptide Enhanced Bone Graft |
| Stryker Corporation | $25.99 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,928.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.